LYTIX.OL
Price:
$10.2
Market Cap:
$696.27M
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company's products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. Lytix Biopharma ASA was incorporated in 2003 and is based in Oslo, Norway.
Industry
Biotechnology
IPO Date
2021-06-14
Stock Exchange
OSL
Ticker
LYTIX.OL
According to Lytix Biopharma AS’s latest financial reports and current stock price. The company's current PE Ratio is -9.11. This represents a change of -10.13% compared to the average of -10.14 of the last 4 quarters.
The mean historical PE Ratio of Lytix Biopharma AS over the last ten years is -10.47. The current -9.11 PE Ratio has changed 8.60% with respect to the historical average. Over the past ten years (40 quarters), LYTIX.OL's PE Ratio was at its highest in in the June 2023 quarter at -2.31. The PE Ratio was at its lowest in in the March 2021 quarter at -506.00.
Average
-10.47
Median
-11.08
Minimum
-22.23
Maximum
-2.28
Discovering the peaks and valleys of Lytix Biopharma AS PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 89.77%
Maximum Annual PE Ratio = -2.28
Minimum Annual Increase = -58.48%
Minimum Annual PE Ratio = -22.23
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -3.38 | 48.15% |
| 2023 | -2.28 | -58.48% |
| 2022 | -5.49 | -50.45% |
| 2021 | -11.08 | -35.29% |
| 2020 | -17.12 | -22.98% |
| 2019 | -22.23 | 89.77% |
The current PE Ratio of Lytix Biopharma AS (LYTIX.OL) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.72
5-year avg
-7.87
10-year avg
-10.47
Lytix Biopharma AS’s PE Ratio is less than Nykode Therapeutics AS (-4.62), less than Hofseth BioCare ASA (-4.79), greater than Navamedic ASA (-14.68), less than BerGenBio ASA (-0.43), less than Arctic Bioscience AS (-2.38), less than PCI Biotech Holding ASA (-0.46), less than ContextVision AB (publ) (29.67), less than Gentian Diagnostics ASA (20.03), greater than Thor Medical ASA (-34298.34), less than Lifecare AS (-1.17),
| Company | PE Ratio | Market cap |
|---|---|---|
| -4.62 | $796.12M | |
| -4.79 | $630.35M | |
| -14.68 | $518.00M | |
| -0.43 | $45.74M | |
| -2.38 | $103.95M | |
| -0.46 | $9.41M | |
| 29.67 | $300.24M | |
| 20.03 | $845.14M | |
| -34298.34 | $1.49B | |
| -1.17 | $100.52M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lytix Biopharma AS using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Lytix Biopharma AS or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Lytix Biopharma AS's PE Ratio?
How is the PE Ratio calculated for Lytix Biopharma AS (LYTIX.OL)?
What is the highest PE Ratio for Lytix Biopharma AS (LYTIX.OL)?
What is the 3-year average PE Ratio for Lytix Biopharma AS (LYTIX.OL)?
What is the 5-year average PE Ratio for Lytix Biopharma AS (LYTIX.OL)?
How does the current PE Ratio for Lytix Biopharma AS (LYTIX.OL) compare to its historical average?